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SUMMARY
Nonarteritic anterior ischemic optic neuropathy (NAION)
has been reported rarely in men after taking sildenafil or
other phosphodiesterase 5 inhibitors for erectile dysfunc-
tion (ED). The incidence of NAION in men receiving
sildenafil treatment for ED was estimated using pooled
safety data from global clinical trials and European obser-
vational studies. Based on clinical trial data in more than
13,000 men and on more than 35,000 patient-years of
observation in epidemiologic studies, we estimated an
incidence of 2.8 cases of NAION per 100,000 patient-
years of sildenafil exposure. This is similar to estimates
reported in general US population samples (2.52 and
11.8 cases per 100,000 men aged  50 years). The data
cited herein do not suggest an increased incidence of
NAION in men who took sildenafil for ED.
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Although nonarteritic anterior ischemic optic neuropathy
(NAION) is the most common acute optic neuropathy in
people older than 50 years, it is actually a rare event in the
general population, with only between 1500 and 6000 cases
reported in the US each year (1,2). It is characterised by
sudden, usually painless, partial loss of vision in one eye (3),
which confers an increased risk of vision loss in the contral-
ateral eye (4). Although a definitive cause has not been
determined, NAION is thought to occur following an idio-
pathic ischemic event involving the short posterior ciliary
arteries that supply blood to the most anterior part of the
optic nerve (3). A complete loss of vision is rare, but partial
loss of visual field or acuity can result from NAION in the
affected eye(s) (5).
Patients who have a ‘disc at risk’ or ‘crowded disc’ (small
cup : disc ratio) (6) are at increased risk for developing
NAION. The optic disc is the region in which the optic
nerve attaches to the back of the eye, and the optic cup is a
smaller circular region within the disc. The optic nerve fibres
that make up the cup allow the central retinal artery to pass
through the optic disc to supply blood to the retina and are
supplied themselves by very small branching vessels from the
posterior ciliary arteries. If the optic nerve fibres are crowded
by a small scleral channel, then an ischemic event in the small
vessels that supply the optic nerve increases the risk of
NAION.
In addition to a crowded disc, other established risk factors
forNAION include agegreaterthan50years andwhite race (an
estimated 95% of cases occur in the latter group) (5).
Hypertension and diabetes also predispose to NAION develop-
ment (5). Other factors that have been hypothesised to associate
with NAION include high cholesterol, arteriosclerosis, stroke,
cardiac andintraocularsurgery,tobaccouse,nocturnalhypoten-
sion, blood loss, glaucoma, elevated homocysteine and sleep
apnea (3). The association between NAION and hypertension,
high cholesterol and diabetes is stronger in individuals younger
than 50 years than in older persons (3).
Many of the risk factors for developing NAION also pre-
dict the occurrence of erectile dysfunction (ED), such as
hypertension, diabetes, hyperlipidemia and smoking (7–9).
Oral phosphodiesterase 5 inhibitors such as sildenafil citrate
(Viagra
 , Pfizer Inc, New York, NY, USA) are the first-line
treatment for ED in patients without contraindications.
Vascular risk factors associated with ED clearly indicate that
consumers of sildenafil are not a random sample of the
general US male population, even of the population of
those aged  50 years. The prevalence of hypertension and
diabetes in the general US adult population, according to data
analysed from the National Health and Nutrition
Examination Survey (NHANES) for 1999–2002, is estimated
to be 29% (10) and 7% (11), respectively. In contrast, in a
large population of ED patients (n ¼ 272,325), the
prevalence of diagnosed hypertension and diabetes in men
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ively (7). Similar baseline prevalences were observed in the
420 patients with NAION eligible for the 26-centre Ischemic
Optic Neuropathy Decompression Trial: 47% and 24%,
respectively (5). Furthermore, the joint occurrence of hyper-
tension and diabetes is higher in the ED population (12.8%)
(7) and in the NAION population (13%) (12) than in the
general population (5.4% [data derived from NHANES
1999–2002 (13)]). Thus, based on the increased prevalence
of underlying NAION risk factors, the incidence of NAION
in men with ED would be expected to be higher than the
incidence of NAION in the general population, and some
men being treated for ED would be expected to coincidentally
experience NAION.
Sildenafil has been approved for the treatment of ED since
1998, and more than 150 million prescriptions have been
written for more than 27 million men worldwide since its
approval (14). The results of more than 100 manufacturer-
sponsored clinical trials of sildenafil for the treatment of ED
demonstrate that it is well tolerated in patients with ED of
various aetiologies and comorbid conditions. However,
because sildenafil may potentiate the hypotensive effects of
nitrates, sildenafil use in patients receiving organic nitrates in
any form, at any time, is contraindicated.
Because of the implied relationship between ED and car-
diovascular disease, the cardiovascular risk associated with
sildenafil use has been studied extensively. Acute or long-
term (as needed) treatment of ED with sildenafil has not
been causally associated with the onset of cardiovascular
ischemic events (15–18).
There have been rare postmarketing reports of patients
developing NAION after taking sildenafil or other phospho-
diesterase 5 inhibitors (i.e. tadalafil [Cialis
 , Lilly ICOS LLC]
and vardenafil [Levitra
 , Bayer Pharmaceuticals Corporation])
for ED. Consequently, the US Food and Drug Administration
and several other regulatory agencies requested that the pre-
scribing information for all three marketed phosphodiesterase 5
inhibitors be updated. The manufacturer has modified the
prescribing information for Viagra globally. The Viagra US
prescribing information was updated (Adverse Reactions/
Postmarketing Experience section) as follows:
NAION, a cause of decreased vision including permanent
loss of vision, has been reported rarely postmarketing in
temporal association with the use of phosphodiesterase
type 5 (PDE5) inhibitors, including VIAGRA. Most,
but not all, of these patients had underlying anatomic or
vascular risk factors for developing NAION, including
but not necessarily limited to low cup to disc ratio
(‘crowded disc’), age over 50, diabetes, hypertension,
coronary artery disease, hyperlipidemia and smoking. It
is not possible to determine whether these events are
related directly to the use of PDE5 inhibitors, to the
patient’s underlying vascular risk factors or anatomical
defects, to a combination of these factors or to other
factors (19).
The Precautions/Information for Patients section of US
prescribing information was also updated, directing physi-
cians to ‘advise patients to stop use of all PDE5 inhibitors,
including VIAGRA, and seek medical attention in the event
of a sudden loss of vision in one or both eyes’ (19) and to
‘discuss with patients the increased risk of NAION in indivi-
duals who have already experienced NAION in one eye,
including whether such individuals could be adversely
affected by the use of vasodilators, such as PDE5 inhibitors’
(19).
Although no cases of NAION have been reported in
patients treated with Revatio
  (sildenafil citrate, Pfizer Inc,
New York, NY, USA) for pulmonary hypertension, the man-
ufacturer has also modified the Revatio prescribing informa-
tion (20).
Spontaneous reports, while useful for identifying potential
signals of drug adverse events, are subject to a number of
limitations. Spontaneous reports may under-report or over-
report events; may lack medical confirmation; can be influ-
enced by factors such as time on market, popularity of a drug,
severity of event, or media attention; and cannot provide
incidence rates. To better understand this event in men who
use sildenafil, we used pooled global clinical trial and
European epidemiologic data to compare the estimated inci-
dence of NAION in the general US population of men with
the estimated incidence in men who took sildenafil for ED
worldwide.
INCIDENCE OF NAION IN THE GENERAL US
POPULATION
Only two studies have investigated the incidence of sponta-
neous NAION in the general US population. As part of the
Rochester Epidemiology Project conducted from 1981 to
1990, Hattenhauer et al. (1) conducted a retrospective analy-
sis of residents of Olmstead County, MN, aged 50 years or
older. Only 22 NAION cases were observed, which yielded
an annual estimated incidence in men and women of 10.3
cases (95% confidence interval [CI], 6.5–15.6) per 100,000
population aged  50 years. The estimated incidence was
slightly higher among men [11.8 per 100,000 aged  50
years (95% CI, 5.9–21.1)] compared with women [9.2 per
100,000 aged  50 years (95% CI, 4.6–16.5)].
Johnson and Arnold (2) sampled a larger population in two
different regions of the US, resulting in greater racial diversity
and a more accurate representation of US population.
Monthly written surveys were sent during a 12-month period
to an average of 198 ophthalmologists in Missouri and during
a 6-month period to an average of 336 ophthalmologists in
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provided an estimated annual NAION incidence in men
and women of 2.3 cases per 100,000 population aged  50
years (95% CI, 1.78–2.82) (2). Similar to the results of
Hattenhauer et al., the estimated incidence was slightly higher
among men [2.52 per 100,000 men aged  50 years (95% CI,
1.69–3.33)] than in women [2.14 per 100,000 women aged
 50 years (95% CI, 1.48–2.81)].
Follow-up telephone interviewing to resolve 130 of 579
nonresponses from the first 5 months of the Missouri survey
yielded one additional case of NAION. The results from this
follow-up sample were extrapolated to the 1293 nonresponses
during the entire 12-month Missouri survey, resulting in 10
additional cases and a corrected estimated annual incidence of
3.06 per 100,000 men and women aged  50 years (2).
INCIDENCE OF NAION IN STUDIES OF
SILDENAFIL
To determine the incidence of NAION in men receiving
sildenafil for the treatment of ED, we reviewed safety data
from global clinical trials and European observational studies.
Clinical trial data and epidemiologic data are both necessary
to evaluate a drug’s safety profile. Clinical trial data have the
advantage of capturing more frequent and more detailed
patient assessments than observational epidemiologic studies,
but observational studies generally reflect ‘real-life’ use in a
greater number of patients followed for a longer period of
time. Clinical trials and observational studies both have
mechanisms to reliably capture incident, serious, adverse
events, including cases of NAION.
A review of a collective database of 103 double-blind or
open-label trials of sildenafil conducted between 1993 and
2003, which included more than 13,400 men with ED, 76%
of whom were from non-US (international) sites, revealed no
cases of reported or observed NAION in more than 13,300
patient-years of observation (14).
The International Men’s Health Study, a prospective cohort
study of 3813 men (mean age 57 years; range 18–100 years) who
received a sildenafil prescription in Germany, France, Spain or
Sweden was conducted by the manufacturer between 2001 and
2004 (21). This cohort study had broad inclusion criteria (receipt
of a sildenafil prescription as part of normal care by general
practitioners or urologists) and minimal exclusion criteria (inabil-
ity to understand or complete informed consent or question-
naires). Detailed information on health status was obtained from
participants via a quarterly postal questionnaire, and all serious
events received medical confirmation. No cases of NAION were
reported during 2935 patient-years of follow-up (14).
A study of patients who received sildenafil from the UK
National Health Service was independently conducted by the
Drug Safety Research Unit at the University of Southampton
between 1998 and 2001 (22–24). In this prescription event
monitoring (PEM) study, physicians were asked to provide,
via postal questionnaire, brief demographic and clinical infor-
mation on patients who had filled an initial sildenafil pre-
scription between September 1998 and March 1999 (phase I)
and April 1999 and August 1999 (phase II). Response rates
were typical of a PEM study and ranged from 54.7% to
61.0%. The mean follow-up time was 6.0 months for the
5601 patients in phase I and 17.5 months for the 22,473
patients in phase II. One case of NAION was reported to the
Drug Safety Research Unit during the 35,500 patient-years of
observation (24,25). This patient was 61 years of age, had
significant predisposing factors for NAION (i.e. a smoker
being treated for hypertension, ischemic heart disease diag-
nosed following myocardial infarction and reported multiple
concomitant medications) and did not experience the
NAION event until more than a year (368 days) after first
being prescribed sildenafil. Based on the report of one
NAION case in a total of 35,500 patient-years of observation
in the PEM, the unadjusted incidence of NAION is estimated
to be 2.8 cases per 100,000 patient-years of exposure to
sildenafil.
DISCUSSION
An association between medication use and NAION has been
considered previously but has not been well supported. In a
recent review of the ischemic optic neuropathies, Rucker,
Biousse and Newman concluded, ‘Rarely, medications have
been implicated in the pathogenesis of NAION, including
sumatriptan, sildenafil, amiodarone and nasal decongestants.
Establishing a direct relationship between the use of a specific
medication and NAION is problematic, however, since most
patients have concurrent vascular risk factors and an under-
lying disc-at-risk.’ (3)
Using extensive epidemiologic and clinical trial data, we
estimated an incidence of 2.8 cases of NAION per 100,000
patient-years of exposure to sildenafil for the treatment of ED.
Compared with estimates in general population samples, this
finding is similar to those of Johnson and Arnold (2.52 per
100,000 men aged  50 years initially; 3.06 per 100,000
individuals [men and women] aged  50 years when corrected
for missing respondents) but lower than that of Hattenhauer
et al. (11.8 cases per 100,000 men aged  50 years). Therefore,
the data cited herein do not suggest an increased incidence of
NAION in men who took sildenafil for their ED.
Based on the similar risk profiles for NAION and ED, it
is not unexpected to observe NAION cases in men with ED.
Rather than supporting an increased incidence of NAION
associated with sildenafil use, this analysis of clinical trial
and epidemiologic data representing approximately 52,000
patient-years of observation indicates that the NAION inci-
dence in men with ED who took sildenafil worldwide is
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the general US population. Extensive European epidemio-
logic and global clinical trial data suggest that there is no
increased incidence of NAION associated with sildenafil
use.
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